Lyter DW, Bryant J, Tackeray R, et al. Incidence of human immunodeficiency virus related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 13 (10): 2540–2546, 1995. PubMedCAS Google Scholar
Centers for Disease Control: First 500,000 cases-United States, 1995. Morbid Mortal Weekly Rep 44:849–853, 1995. Google Scholar
Jacobson LP, et al. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individuals. The Second Natl AIDS Malignancy Conference (abstract) S5, 1998. Google Scholar
Wiggins CL, Aboulafia DM, Ryland LM, et al. Decline in HIV-associated Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL) following the introduction of highly active antiretroviral therapy (HAART). The Third Natl AIDS Malignancy Conference (abstract) 21(1): A15, 1999. Google Scholar
Nichols CM, Fraitz CM, Hicks MJ. Treating Kaposi’s lesions in the HIV-infected patient. J Am Dent Assoc 124:78, 1993. PubMedCAS Google Scholar
Huang L, Schnapp LM, Goodman PC, et al. Presentation of Pulmonary Kaposi’s sarcoma (abstract PB 110) in Programs and Abstracts of the 10thInternational Conference on AIDS. 171, 1994. Google Scholar
Niedt GW, Schinella A. Acquired immunodeficiency syndrome clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 109:727–734, 1985. PubMedCAS Google Scholar
Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi’s sarcoma of internal organs. Cancer 75:1376–1385, 1995. ArticlePubMedCAS Google Scholar
Meduri GU, Stover DE, Lee M, et al. Pulmonary Kaposi’s sarcoma in the acquired immune deficiency syndrome. Am J Med 81:11–18, 1986. ArticlePubMedCAS Google Scholar
Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 105:1314, 1994. ArticlePubMedCAS Google Scholar
Lee VW, Fuller JD, O’Brien MJ, et al. Pulmonary Kaposi’s sarcoma in patients with AIDS: scintigraphic diagnosis with sequential thallium and gallium scanning. Radiology 80:409, 1991. Google Scholar
Krown SE, Metroka C, Wernz JC, et al. Kaposi’s sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response and staging criteria. J Clin Oncol 7(9):1201–1207, 1989. PubMedCAS Google Scholar
Krown SE, Testa M, Huang J. AIDS-related Kaposi’s sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification: AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 15(9):3085–3092, 1997. PubMedCAS Google Scholar
Barillari G, Gendelman R, Gallo RC, et al. The tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi’s sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 90:7941, 1993. ArticlePubMedCAS Google Scholar
Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946–954, 1997. PubMedCAS Google Scholar
Olsen SJ, Moore PS. Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) and the etiology of KS. in: Friedman H, Medveczky P, Bendinelli M, eds. Molecular immunology of herpesviruses. New York, NY: Plenum Publishing Corporation (in press). Google Scholar
Moore PS, Kingsley LA, Holmberg SP, Spira T, Gupta P, Hoover D, Parry JP, Conley LJ, Jaffe HW, Chang Y. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. AIDS 10:175–180, 1996. ArticlePubMedCAS Google Scholar
Looney DJ, Wikthe W, Feigal E, et al. Relationship of HHV-8 peripheral blood mononuclear cell burden to immunodeficiency, opportunistic infections, response to therapy and stage of Kaposi’s sarcoma. lstNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A35, 1997 (abstr 75). Google Scholar
Quinlevan B, Ye D, Wehkie R, et al. Frequency of HHV-8 detection in peripheral blood cells in patients with Kaposi’s sarcoma. 1stNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A22, 1997 (abstr 24). Google Scholar
Tamm M, Reichenberger F, McGandy C, Stalder A, Tietz A, Dalquen P, Perruchoud AP, Cathomas G Diagnosis of pulmonary Kaposi’s sarcoma by detection of human herpes virus 8 in bronchoalveolar lavage. Am J Respir Crit Care Med 157:458–63, 1997. Google Scholar
Feigal EG, Von Roenn JH, Justice K, et al. Kaposi’s sarcoma response criteria identified by the National Cancer Institute, food and Drug Administration and the AIDS Malignancy Consortium. 1stNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A22, 1997 (abstr 24). Google Scholar
Volm MD, Wernz J. Patients with advanced AIDS-related Kaposi’s sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy. Proceedings of ASCO 16, 1997 (abstr 162). Google Scholar
Routy JP, Urbanek A, MacLeod J, et al. Significant regression of Kaposi’s sarcoma following initiation of an effective antiretroviral combination treatment. 1stNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A22, 1997 (abstr 23). Google Scholar
Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi’s sarcoma in AIDS. Eur J Cancer 31B(4):280–285, 1995. CAS Google Scholar
Webster GF. Local therapy for mucocutaneous Kaposi’s sarcoma in patients with acquired immunodeficiency syndrome. Dermatol Surg 21:205–208, 1995. PubMedCAS Google Scholar
Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS associated Kaposi’s sarcoma. Int J Radiat Oncol 27:1057–1061, 1993. ArticleCAS Google Scholar
Piedbois P, Frikha H, Martin L, et al. Radiotherapy in the management of epidemic Kaposi’s sarcoma. Int J Radiat Oncol 30(5):1207–1211, 1994. ArticleCAS Google Scholar
Swift PS. Radiation therapy in the management of HIV-related KS. Hematology/Oncology Clinics of North America 10(5): 1069–1080, 1996. ArticlePubMedCAS Google Scholar
Conant M. Topical Alitretinoin gel as treatment for cutaneous lesions of patients with AIDS-related Kaposi’s sarcoma: Results of two multi-center, double-blind, vehicle-controlled trials. 6thConf on Retroviruses and Opportunistic Infections, Chicago, IL, 1999 (abstr 205). Google Scholar
Ligand Pharmaceuticals Inc. Manufacturer’s package insert. February 1999. Google Scholar
Volberding PA, Mitsuyasu RT, Golando JP, et al. Treatment of Kaposi’s sarcoma with interferon alfa-2b (Intron A). Cancer 59:620–625, 1987. ArticlePubMedCAS Google Scholar
Mauss S, Jablonowski H. Efficacy, safety, and tolerance of low-dose, long-term interferon alpha-2b and zidovudine in early stage AIDS-associated Kaposi’s sarcoma. J Acq Imm Def Syn 10:157–162, 1995. CAS Google Scholar
Fischl MA, Finkelstein DM, He W, et al. A phase II study of recombinant human interferon alpha-2b and zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acq Imm Def 11:379–385, 1996. CAS Google Scholar
Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alpha with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network Study. J Clin Oncol 16(5):1736–1742, 1998. PubMedCAS Google Scholar
Paredes J, Kahn JO, Tong WP, et al. Weekly oral etoposide in patients with Kaposi’s sarcoma associated with human immunodeficiency virus infection: A phase 1 multicenter trial of the AIDS Clinical Trials Group. J Acq Imm Def Syn 9:138–144, 1995. CAS Google Scholar
Volberding PA, Abrams DI, Conant M, et al. Vinblastine therapy for Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Int Med 103:335–338, 1985. PubMedCAS Google Scholar
Mintzer DM, Real FX, Jovino L, et al. Treatment of Kaposi’s sarcoma and thrombocytopenia with vincristine in patients with acquired immune deficiency syndrome. Ann Int Med 102:200–202, 1985. PubMedCAS Google Scholar
Caumes E, Guermonprez G, Katlama C, et al. AIDS-associated mucocutaneous Kaposi’s sarcoma treated with bleomycin. AIDS 6:1483–1487, 1992. ArticlePubMedCAS Google Scholar
Remick SC, Reddy M, Herman D, et al. Continuous infusion bleomycin in AIDS-related Kaposi’s sarcoma. J Clin Oncol 12:1130–1136, 1994. PubMedCAS Google Scholar
Fischl MA, Krown SE, O’Boyle KP, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi’s sarcoma. J Acq Imm Def Syn 6:259–264, 1993. CAS Google Scholar
Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi’s sarcoma with paclitaxel. Lancet 346:26–28, 1995. ArticlePubMedCAS Google Scholar
Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 17:1876–1883, 1997. Google Scholar
Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acq Imm Def Syn 7:463–468, 1994. CAS Google Scholar
Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 13:914–920, 1995. PubMedCAS Google Scholar
Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi’s sarcoma. Lancet 341:1242–1243, 1993. ArticlePubMedCAS Google Scholar
Tulpule A, Yung RC, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi’s sarcoma. J Clin Oncol 16: 3369–374, 1998. Google Scholar
Gill PS, Rarick MU, Espina B, et al. Advanced acquired immunodeficiency syndrome-related Kaposi’s sarcoma: Results of pilot studies using combination chemotherapy. Cancer 65:1074–1078, 1990. ArticlePubMedCAS Google Scholar
Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi’s sarcoma. J Clin Oncol 14:2353–2364, 1996. PubMedCAS Google Scholar
Gill PS, Ravick MU, Bernstein-Singer M, et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Ann J Clin Oncol 13:315319, 1990. Google Scholar
Kaplan L, Abrams D, Volberding P. Treatment of Kaposi’s sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 70:1121–1122, 1986. PubMedCAS Google Scholar
Laubenstein LJ, Krigel RL, Odajnyk CM, et al. Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 2:1115–1120, 1984. PubMedCAS Google Scholar
Gompels MM, Hill A, Jenkins P, et al. Kaposi’s sarcoma in HIV infection treated with vincristine and bleomycin. AIDS 6:1175–1180, 1992. ArticlePubMedCAS Google Scholar
Sloand E, Kumar PN, Pierce PF. Chemotherapy for patients with pulmonary Kaposi’s sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. South Med J 86:1219–1224, 1993. ArticlePubMedCAS Google Scholar
Bakker PJM, Danner SA, Napel CH, et al. Treatment of poor prognosis epidemic Kaposi’s sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocyte-monocyte colony stimulating factor (rh GM-CSF). Eur J Cancer 31A:188–192, 1995. ArticlePubMedCAS Google Scholar
Northfelt DW, Dezube B, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16:2445–2451, 1998. PubMedCAS Google Scholar
Stewart JSW, Jabonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol 16:683–691, 1998. PubMedCAS Google Scholar
Mitsuyasu R, Von Roenn J, Krown S, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi’s sarcoma (AIDS-KS): AIDS Clinical Trials Group (ACTG) protocol 286 (abstract) Proc Am Soc Clin Oncol 16:55a, 1997. Google Scholar
Gabizon A, Catane R, Uziely B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992, 1994. PubMedCAS Google Scholar
Ross M, Gill PS, Espina BM, et al. Liposomal daunorubicin (DaunoXome) in the treatment of advanced AIDS-related Kaposi’s sarcoma: Results of a phase II study (abstract PoB 3123). Int Conf AIDS 8:B107, 1992. Google Scholar
Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of Doxil (pegylated liposomal doxorubicin) in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol (abst 843) 15:303, 1996. Google Scholar
Gordon KB, Tajuddin A, Guitart J, et al. Hand foot syndrome associated with liposome encapsulated doxorubicin therapy. Cancer 75(8):2169–2173, 1995. ArticlePubMedCAS Google Scholar
Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, et al. Fumagillin analog (TNP-470) in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trials Group trial. J Clin Oncol 16:1444–1449, 1998. PubMedCAS Google Scholar
Fife K, Howard MR, Gracie F, Phillips RH, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titre. Intl J STD & AIDS 9:751–755, 1998. ArticleCAS Google Scholar
Gelsby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi’s sarcoma: Data from the Multicenter AIDS Cohort Study. AIDS 10:1101–1105, 1996. Google Scholar
Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. J Clin Investig 99:2082–2086, 1997. Article Google Scholar
Kedes DH, Ganem D: Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Investig 99:2082–2086, 1997. ArticlePubMedCAS Google Scholar